Abstract
In stage III melanoma, neoadjuvant (neoadj) IPI + NIVO induces high pathologic response rates (pRR 72-78%), which is associated with long-term RFS. Pts with a low baseline IFN-γ sign are less likely to respond (pRR 55%). Domatinostat (DOM), a class I histone deacetylase inhibitor, increased intratumoral T cell infiltration and the IFN-γ sign expression in melanoma. DONIMI tests neoadj combinations of NIVO ± IPI with DOM stratified according to the IFN-γ sign of baseline biopsies in stage IIIB-D nodal melanoma.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
